Please sign in to follow a disease.
Reproductive system neoplasm
MONDO:0006054A benign or malignant, primary or metastatic neoplasm affecting the male and female reproductive system.
Also known as: neoplasm of reproductive system, neoplasm of the reproductive system, reproductive neoplasm, reproductive system neoplasm, reproductive system neoplasm (disease), reproductive system tumor, reproductive system tumour, reproductive tumor
5170 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 861 trials in this tab.
-
Ovarian cancer vaccine shows promise in early trial
⭐️ VACCINE ⭐️ CompletedThis early-stage study tested a vaccine called DCP-001 in 17 women with a serious type of ovarian cancer who had already completed standard treatment. The goal was to see if the vaccine is safe and can boost the immune system to recognize and fight cancer cells. Researchers measu…
Phase: PHASE1 • Sponsor: University Medical Center Groningen • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
Custom-Made cancer vaccine tested in 25 patients
⭐️ VACCINE ⭐️ CompletedThis study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.
Phase: PHASE1 • Sponsor: Aaron Miller • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
Hormone shot timing may affect recovery after prostate cancer treatment
Disease control CompletedThis trial compares two types of hormone injections given before prostate brachytherapy (internal radiation) for early-stage prostate cancer. One injection lasts one month, the other three months, and both are used to lower testosterone to make radiation more effective. The study…
Phase: NA • Sponsor: University of British Columbia • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Can a website help cancer survivors live healthier? large study tests online lifestyle coaching
Disease control CompletedThis study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New radiation approach aims to tame prostate cancer with fewer side effects
Disease control CompletedThis study tests a type of radiation called high-dose brachytherapy for men with prostate cancer that hasn't spread. Doctors place tiny radioactive sources directly into the prostate to deliver a strong dose to the tumor while sparing nearby healthy tissue. The goal is to control…
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Which radiotherapy technique offers best value for pelvic cancers?
Disease control CompletedThis trial compares three modern radiotherapy techniques—helical tomotherapy and two types of dynamic arc therapy (RapidArc and VMAT)—for treating prostate, cervical, and anal canal cancers that require pelvic lymph node irradiation. The goal is to determine which method is most …
Phase: NA • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New chemo cocktail targets Hard-to-Treat testicular cancer
Disease control CompletedThis study tests a combination of three chemotherapy drugs—gemcitabine, oxaliplatin, and paclitaxel—in people with advanced testicular cancer that has not responded to standard cisplatin-based treatment or has returned after treatment. The goal is to see if this drug combination …
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug duo aims to shrink prostate tumors before surgery
Disease control CompletedThis study tests two drugs, saruparib and darolutamide, given alone or together before prostate removal surgery in men with newly diagnosed prostate cancer. The goal is to see how these drugs affect cancer cells and check for side effects. About 120 men with localized, higher-ris…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New drug combo aims to stall prostate cancer in chinese men
Disease control CompletedThis study tests whether adding darolutamide to standard hormone therapy (ADT) helps Chinese men with a high-risk form of prostate cancer that has not spread but is no longer responding to hormone therapy alone. Darolutamide blocks the effects of male hormones on cancer cells, po…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Triple immunotherapy attack shows promise against Hard-to-Treat HPV cancers
Disease control CompletedThis study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Nanoparticle chemo and DNA-Repair blocker join forces against tough cancers
Disease control CompletedThis trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prosta…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a Low-Carb diet help fight endometrial cancer?
Disease control CompletedThis study looks at whether a ketogenic diet—a very low-carbohydrate diet that forces the body to burn fat for energy—is safe and tolerable for overweight or obese women with newly diagnosed endometrial cancer before they have surgery. Nineteen participants will either follow the…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Immunotherapy and chemotherapy join forces to fight recurrent ovarian cancer
Disease control CompletedThis phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy drug carboplatin can prevent ovarian, fallopian tube, or primary peritoneal cancer from progressing after a blood test shows it may have returned. The study includes …
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could a targeted drug shrink advanced cervical tumors?
Disease control CompletedThis phase 2 trial tests the drug cabozantinib in women with advanced or metastatic cervical cancer that has worsened after platinum-based chemotherapy. The study aims to see if cabozantinib can control the disease and how safe it is, particularly regarding risks like fistulas. P…
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New radioactive drug targets prostate cancer in early trial
Disease control CompletedThis small, completed Phase 1 study tested a single injection of a radioactive drug called Lutetium-177 BQ7876 in 7 men with prostate cancer. The main goals were to see how the drug spreads in the body, how much radiation reaches tumors, and whether it is safe. Because it is very…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Experimental DNA vaccine targets HPV to fight precancerous cervical cells
Disease control CompletedThis early-stage trial tested a DNA vaccine called NWRD08 in 9 women with high-grade cervical lesions caused by HPV types 16 or 18. The vaccine was given as a shot followed by a mild electrical pulse to help cells take it up. The main goal was to check safety and see if the vacci…
Phase: PHASE1 • Sponsor: Newish Technology (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for advanced bladder cancer? bevacizumab combo tested
Disease control CompletedThis phase 3 trial tested whether adding bevacizumab (Avastin) to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced urinary tract cancer live longer. 506 patients with cancer that had spread or could not be removed by surgery took part. The study compar…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail aims to make inoperable abdominal cancers operable
Disease control CompletedThis phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could a depression drug fight prostate cancer?
Disease control CompletedThis phase 2 trial tested phenelzine sulfate (Nardil), an antidepressant, in 26 men with prostate cancer that returned after initial treatment but hadn't spread. The goal was to see if the drug could lower PSA levels, a marker of cancer activity. Researchers measured how many pat…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
One-Patient trial tests keytruda for rare ovarian cancer
Disease control CompletedThis study tested the drug pembrolizumab (Keytruda) as a follow-up treatment for one patient with a rare type of ovarian cancer called small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The goal was to see if the drug could help keep the cancer from coming back. Beca…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail targets Hard-to-Treat ovarian and endometrial cancers
Disease control CompletedThis early-stage trial tested two drugs—niraparib and copanlisib—in 31 people with recurrent endometrial, ovarian, peritoneal, or fallopian tube cancer. The goal was to find the safest dose and see how well patients tolerated the combination. Both drugs work by blocking enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for tough cancers
Disease control CompletedThis study tested a new drug called CT7001, alone or with other cancer treatments, in 124 people with advanced solid tumors like breast and prostate cancer. The main goal was to check safety and side effects. The drug is taken by mouth and aims to control the disease, not cure it…
Phase: PHASE1, PHASE2 • Sponsor: Carrick Therapeutics Limited • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Heated chemo during surgery may curb return of rare uterine cancer
Disease control CompletedThis phase 2 trial tested whether giving heated chemotherapy directly into the abdomen during surgery, followed by standard chemo, could help prevent uterine leiomyosarcoma from coming back. Seventeen women with locally recurrent cancer took part. The goal was to see if this comb…
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to halt prostate Cancer's return
Disease control CompletedThis study tested whether adding an experimental drug (MK-2206) to the standard hormone therapy bicalutamide can better control prostate cancer in men whose PSA levels are rising after initial treatment. About 108 men with recurrent prostate cancer took part. The goal was to see …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for indian men with advanced prostate cancer: enzalutamide under study
Disease control CompletedThis study tested the safety and effectiveness of enzalutamide (Xtandi) in 52 Indian men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy. Participants took enzalutamide daily while continuing hormone therapy. The main goal was to see how …
Phase: PHASE4 • Sponsor: Astellas Pharma Inc • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Prostate cancer combo: does adding chemo after surgery keep cancer away?
Disease control CompletedThis study looked at 612 men with prostate cancer that had been removed by surgery. It compared standard treatment (hormone therapy plus radiation) against the same treatment plus the chemotherapy drug docetaxel. The goal was to see if adding chemo helps keep the cancer from comi…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Heated chemo during second surgery shows promise for ovarian cancer
Disease control CompletedThis study looked at whether giving heated chemotherapy directly into the abdomen during a second-look surgery is possible for people with ovarian, fallopian tube, or peritoneal cancer. Ten participants who had already received standard treatment were enrolled. The goal was to se…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Zapping prostate tumors with extra radiation: a new targeted approach
Disease control CompletedThis study tested whether giving a higher dose of radiation specifically to the visible tumor inside the prostate could improve cancer control in men with localized prostate cancer. Eighty-five men either received a standard radiation plan with an extra boost to the tumor or a co…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New PET scan hunts down hidden prostate cancer for precision radiation
Disease control CompletedThis study tested a new type of PET/MRI scan that uses a special tracer to find small spots of prostate cancer that standard scans miss. Men with a rising PSA after prostate surgery and radiation received targeted radiation to those spots. The goal was to see if this approach can…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to keep aggressive prostate cancer in check
Disease control CompletedThis study tests whether the drug olaparib can help control aggressive variant prostate cancer when given after initial chemotherapy. About 96 men will receive cabazitaxel, carboplatin, and prednisone first, then either olaparib or observation. The goal is to see if olaparib exte…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise in Tough-to-Treat prostate cancer
Disease control CompletedThis completed phase II trial tested whether a targeted chemotherapy drug (abemaciclib) and an immunotherapy drug (atezolizumab), alone or together, can shrink or slow advanced prostate cancer that no longer responds to hormone therapy. Nineteen men with metastatic castration-res…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Timing matters: early platelet booster may prevent dangerous drops in cervical cancer treatment
Disease control CompletedThis study looked at when to start giving a drug called rhTPO to cervical cancer patients whose platelet levels drop during chemoradiation. The goal was to see if starting treatment earlier could prevent severe low platelet counts. Researchers studied 75 patients and compared two…
Phase: NA • Sponsor: Mei Feng • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill combo aims to shrink tough prostate tumors
Disease control CompletedThis early-stage study tests two oral drugs (darolutamide and abemaciclib) plus standard hormone therapy in men with high-risk prostate cancer that has spread or may come back. The first part finds the safest dose; the second checks if the combination can shrink or eliminate tumo…
Phase: PHASE1 • Sponsor: Praful Ravi, MB BCHir, MRCP • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase: PHASE1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a cheaper copy of a key chemo drug work just as well?
Disease control CompletedThis study compares a new formulation of the chemotherapy drug doxorubicin (Doxopeg) to the standard version (Caelyx) in people with advanced ovarian cancer or metastatic breast cancer. The goal is to see if the two drugs are absorbed and processed by the body in the same way. Pa…
Phase: PHASE1 • Sponsor: Zodiac Produtos Farmaceuticos S.A. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to prevent deadly bowel blockages in ovarian cancer
Disease control CompletedThis completed phase 2 trial tested whether the drug cediranib, given with chemotherapy, is safe for women with advanced ovarian cancer who are at risk of bowel obstruction. 30 participants received the combination. The study focused on whether the treatment caused serious bowel …
Phase: PHASE2 • Sponsor: Prof Gordon Jayson • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Prostate cancer drug showdown: which is safer for the heart?
Disease control CompletedThis completed Phase 3 study compared the risk of major heart problems between two hormone therapies—relugolix (a pill) and leuprolide (an injection)—in 387 men with prostate cancer. The trial was stopped early by the sponsor, but enrolled patients could continue treatment for up…
Phase: PHASE3 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Old chemo drug shows promise for genetic subtype of prostate cancer
Disease control CompletedThis phase 2 trial tested the chemotherapy drug carboplatin in 16 men with metastatic castration-resistant prostate cancer that has specific gene changes in the homologous recombination pathway. The goal was to see if carboplatin could shrink tumors or lower PSA levels. The study…
Phase: PHASE2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Cancer-Fighting virus shows promise in Hard-to-Treat ovarian cancer
Disease control CompletedThis study tested a new immunotherapy called Olvi-Vec, which uses a modified virus to attack cancer cells, in 46 patients with ovarian cancer that had come back or stopped responding to standard treatments. The goal was to see if the treatment was safe and could slow tumor growth…
Phase: PHASE1, PHASE2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for advanced endometrial cancer: immunotherapy combo trial shows promise
Disease control CompletedThis phase 2 study tested a drug called retifanlimab, which helps the immune system attack cancer, either alone or combined with other targeted drugs. It enrolled 206 women with advanced or metastatic endometrial cancer that had worsened after platinum-based chemotherapy. The goa…
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cocktail of three drugs tested for tough bladder cancers
Disease control CompletedThis early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental CAR T-Cell therapy targets rare testicular cancer
Disease control CompletedThis phase 2 study tested a new treatment for nonseminomatous germ cell tumors (a type of testicular cancer) that had not responded to standard therapy. The treatment used the patient's own immune cells (T cells) that were genetically modified to recognize and attack cancer cells…
Phase: PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo aims to shrink fibroids in pregnant women
Disease control CompletedThis study tested a drug called SB-UF, which combines hormones and a plant extract, to see if it can shrink uterine fibroids in pregnant women. 66 women took the drug or a placebo throughout their pregnancy. The goal was to reduce fibroid size and help them disappear, which could…
Phase: PHASE4 • Sponsor: Trieu, Nguyen Thi, M.D. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Experimental vaccine targets Hard-to-Treat cancers in first human test
Disease control CompletedThis early-phase trial tested a new type of vaccine made from a patient's own immune cells (dendritic cells) that are engineered to target a protein called WT1 found in many cancers. Ten people with advanced esophageal, pancreatic, ovarian, or liver cancer received six vaccines o…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail shows promise in Tough-to-Treat prostate cancer
Disease control CompletedThis study tested a combination of two targeted drugs (pertuzumab and trastuzumab) plus a chemotherapy drug (enzalutamide) in 7 men with advanced prostate cancer that had stopped responding to standard treatments. The goal was to see if the combination could shrink or slow the gr…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New adaptive radiotherapy aims to shrink treatment margins for uterine cancers
Disease control CompletedThis study tested a new type of radiation therapy that adjusts the treatment plan daily based on the patient's anatomy. It included 15 women with endometrial or cervical cancer who had surgery and needed radiation. The goal was to see if smaller treatment margins could be used sa…
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Radioactive drug shows promise for tough prostate cancer
Disease control CompletedThis study tested a radioactive drug called 177Lu-PSMA-617 in 62 Chinese men with advanced prostate cancer that had spread and stopped responding to hormone therapy and chemotherapy. The drug targets a protein on cancer cells and delivers radiation directly to them. Researchers m…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Common painkiller may boost Chemo's power against cancer
Disease control CompletedThis early-phase study tested whether adding indomethacin, a common anti-inflammatory drug, to standard platinum-based chemotherapy is safe for people with colorectal, esophageal, or ovarian cancers. The 13 participants received escalating doses of indomethacin alongside their ch…
Phase: PHASE1 • Sponsor: UMC Utrecht • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Minimally invasive surgery vs. open surgery for cervical cancer: which is better?
Disease control CompletedThis study compared two surgical approaches for early-stage cervical cancer: laparoscopic-assisted (minimally invasive) and open abdominal hysterectomy. Sixty women with stage IA1 to IB1 cervical cancer were randomly assigned to one of the two surgeries. Researchers measured surg…
Phase: NA • Sponsor: Zagazig University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill shows promise against tough prostate cancer
Disease control CompletedThis study tested a drug called ARN-509 in 127 men with advanced prostate cancer that had stopped responding to standard hormone therapy. The goal was to find a safe dose and see if the drug could lower PSA levels, a marker of cancer activity. The drug works by blocking male horm…
Phase: PHASE1, PHASE2 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough leukemia: targeted drug combo shows promise in large trial
Disease control CompletedThis large phase III trial tested whether adding the targeted drug dasatinib to standard chemotherapy improves outcomes for children and young adults with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (B-ALL), including those with certain genetic mutations. Nearly…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Immunotherapy combo shows promise for tough pituitary tumors
Disease control CompletedThis phase 2 trial tested two immunotherapy drugs, nivolumab and ipilimumab, in 10 patients with aggressive pituitary tumors that worsened after surgery and radiation. The goal was to see if the combination could shrink tumors or slow their growth. Researchers also monitored side…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New NanoKnife treatment shows promise for prostate cancer
Disease control CompletedThis study tested a device called NanoKnife to treat prostate cancer in 121 men with intermediate-risk disease. The goal was to safely destroy cancer tissue while avoiding major side effects. Researchers checked if the treated area was cancer-free after 12 months and tracked any …
Phase: NA • Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New antibody drug takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug called PF-07257876 in 29 people with advanced lung, head/neck, or ovarian cancers that had stopped responding to other treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals wer…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Major trial tests if abdominal chemo beats IV for tough cancers
Disease control CompletedThis large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New HIV vaccine and antibody cocktail aims to free patients from daily meds
Disease control CompletedThis study tested a two-part vaccine (Ad26.Mos4.HIV and MVA-BN-HIV) combined with three broadly neutralizing antibodies (PGT121, PGDM1400, VRC07-523LS) in 28 adults with HIV who were already on suppressive antiretroviral therapy (ART). The goal was to see if this combination coul…
Phase: PHASE1, PHASE2 • Sponsor: Boris Juelg, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail shows promise for tough prostate cancer
Disease control CompletedThis phase II trial tested a combination of three drugs—carboplatin, cabazitaxel, and abiraterone—in 61 men with high-volume metastatic prostate cancer that still responds to hormone therapy. The goal was to see how many men had no cancer growth after one year. The study also tra…
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a few weeks of radiation be enough for recurrent prostate cancer?
Disease control CompletedThis early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase: PHASE1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cocktail of three drugs shows promise for Tough-to-Treat uterine cancer
Disease control CompletedThis early-phase trial tested a combination of three drugs—olaparib, metformin, and cyclophosphamide—in 35 women with recurrent advanced endometrial cancer that had already been treated with chemotherapy. The goal was to find a safe dose and see if the combination could stop the …
Phase: PHASE1, PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New radiation schedule may cut treatment time for prostate cancer patients
Disease control CompletedThis phase II trial tested a shorter course of higher-dose radiation (hypofractionation) in 53 men with high-risk prostate cancer who had already had their prostate removed. The goal was to see if this approach could control cancer while reducing side effects. Participants also r…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo aims to slow advanced prostate cancer
Disease control CompletedThis study tests whether adding an immunotherapy drug called lorigerlimab to standard chemotherapy (docetaxel) can help men with a tough-to-treat type of prostate cancer live longer without their disease getting worse. About 150 men with metastatic castration-resistant prostate c…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could a third chemo drug tame advanced endometrial cancer?
Disease control CompletedThis study looked at whether adding a drug called epirubicin to the standard two-drug chemotherapy (paclitaxel and carboplatin) helps people with advanced endometrial cancer. Sixty patients were enrolled to see if the three-drug combo is better at controlling the disease before s…
Phase: NA • Sponsor: Sohag University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Freezing prostate tumors shows promise in 354-Patient study
Disease control CompletedThis study followed 354 men with low- to intermediate-risk prostate cancer who chose to freeze only the cancerous half of their prostate (hemi-gland cryoablation). Researchers tracked how well the treatment controlled the cancer and how it affected urinary function and quality of…
Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New combo therapy and advanced scans aim to improve prostate cancer detection and treatment
Disease control CompletedThis study tested a combination of three hormone-blocking drugs (enzalutamide, abiraterone, and standard hormone therapy) given before surgery in 12 men with newly diagnosed prostate cancer that hasn't spread. Researchers also used special PET/CT scans with a new tracer to see if…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Shorter radiation after prostate surgery may be just as good
Disease control CompletedThis study tested whether a shorter course of higher-dose radiation (hypofractionated) works as well as standard radiation after prostate removal in 296 men with prostate cancer. The main focus was on quality of life, especially urinary and bowel function. The goal is to find a t…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New X-Ray tracking could sharpen prostate cancer radiation
Disease control CompletedThis study tested a new X-ray monitoring technique (KIM) during prostate cancer radiation therapy. The goal was to see if it helps doctors aim more precisely at the tumor while reducing harm to healthy tissue. 49 men with low- or intermediate-risk prostate cancer took part. The a…
Phase: NA • Sponsor: University of Sydney • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Keytruda after chemo shows promise in Hard-to-Treat ovarian cancer
Disease control CompletedThis phase 2 trial tested whether the immunotherapy drug pembrolizumab (Keytruda) could help keep cancer from growing in people with platinum-resistant ovarian, fallopian tube, or peritoneal cancer. After initial chemotherapy with paclitaxel, 20 participants received pembrolizuma…
Phase: PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo aims to stop high-risk prostate cancer in its tracks
Disease control CompletedThis study tested whether adding the drug niraparib to standard radiation and hormone therapy can help prevent high-risk prostate cancer from coming back. Niraparib blocks a protein that cancer cells use to repair their DNA, which may kill them. The trial enrolled 22 men with agg…
Phase: PHASE1, PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Prostate cancer radiation cut to just 5 sessions in new trial
Disease control CompletedThis phase I trial tested a new type of radiation therapy for low- and intermediate-risk prostate cancer that delivers a higher dose each day, completing treatment in just 5 sessions over 2 weeks instead of the usual 45-48. The study enrolled 120 participants to check the safety …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could an immunotherapy drug replace hormone therapy for some prostate cancers?
Disease control CompletedThis phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 8 men whose prostate cancer had returned after surgery or radiation, shown by rising PSA levels. The men had specific genetic changes (MMR deficiency or CDK12 alteration) that might make their cancers more sen…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase: PHASE1, PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New combo therapy shows promise for tough prostate cancers
Disease control CompletedThis study tested a new drug (BXCL701) combined with an immunotherapy (pembrolizumab) in 98 men with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combination could shrink tumors or slow the disease. This is a disease control appr…
Phase: PHASE1, PHASE2 • Sponsor: BioXcel Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Zapping resistant tumors: could targeted radiation buy more time for prostate cancer patients?
Disease control CompletedThis trial tested whether a precise type of radiation called SBRT could slow the growth of metastatic prostate cancer in men whose disease was starting to worsen despite hormone therapy. 86 men with one or two growing tumors received SBRT while continuing their current hormone dr…
Phase: NA • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New birth control pill aims to help women with painful conditions
Disease control CompletedThis study tested whether a daily combination pill (relugolix, estradiol, and norethindrone acetate) can prevent pregnancy in women aged 18 to 50 who have uterine fibroids or endometriosis. Over 1,100 women took the pill for up to a year, and researchers counted how many became p…
Phase: PHASE3 • Sponsor: Sumitomo Pharma Switzerland GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for rare penile cancer
Disease control CompletedThis study tested whether a combination of two chemotherapy drugs, gemcitabine and cisplatin, can shrink tumors in people with advanced or metastatic penile cancer. Fifty adults with inoperable or spreading disease took part. The main goal was to see how many patients responded t…
Phase: PHASE2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Turmeric and black pepper extract shows promise in slowing early cancers
Disease control CompletedThis study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New radiation approach shows promise for prostate cancer control
Disease control CompletedThis study tested a new way to give radiation therapy for prostate cancer. It used very precise, high-dose radiation over just five days. The goal was to control the cancer while reducing side effects on the bladder and bowel. 444 men with localized prostate cancer took part, and…
Phase: NA • Sponsor: Fundacao Champalimaud • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug candidate CBX-12 tested in patients with Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard therapies. The main goals were to check the drug's safety, find the best dose, and see if it could sh…
Phase: PHASE1, PHASE2 • Sponsor: Cybrexa Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer
Disease control CompletedThis study tested a radioactive drug called 177Lu-PSMA-617 in 94 Japanese men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers measured how well it shrank tumor…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Cancer drug vismodegib tested for Long-Term use in small study
Disease control CompletedThis study looked at the long-term safety of the cancer drug vismodegib in 19 patients with ovarian cancer, basal cell carcinoma, or metastatic colorectal cancer. All participants had previously taken vismodegib in an earlier Genentech trial and were expected to benefit from cont…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Old drug, new hope: niclosamide combo tackles tough prostate cancer
Disease control CompletedThis early-stage trial tested the safety and best dose of adding niclosamide (a drug used for tapeworm infections) to standard hormone therapy (enzalutamide) in 6 men with advanced prostate cancer that no longer responds to hormone treatment. The goal was to see if the combinatio…
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Ovarian cancer hope: immunotherapy and targeted pill combo tested
Disease control CompletedThis large phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy olaparib (Lynparza) to standard chemotherapy helps women with advanced ovarian cancer that does not have a BRCA mutation. Over 1,300 participants received eithe…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced cancers like breast, ovarian, stomach, colorectal, brain, bile duct, or pancreatic cancer that had stopped responding to standard treatments. The goal was to see if the combo c…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Quick-blast radiation for prostate cancer shows promise in small pilot study
Disease control CompletedThis pilot study tested a new, shorter radiation schedule (ultra-hypofractionation) in 13 men with early-stage prostate cancer. The goal was to see if this approach causes fewer urinary side effects while still controlling the cancer. Participants had low- to intermediate-risk pr…
Phase: NA • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control CompletedThis Phase 2 trial tested an immunotherapy drug called vudalimab, either by itself or combined with standard chemotherapy or targeted therapy, in 72 men with metastatic castration-resistant prostate cancer that had worsened after prior treatments. The main goal was to check safet…
Phase: PHASE2 • Sponsor: Xencor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Steam power: could water vapor zap prostate cancer?
Disease control CompletedThis study tested a device that uses water vapor (steam) to destroy cancerous tissue in the prostate. 32 men with prostate cancer received the treatment just before their scheduled prostate removal surgery. Researchers checked how well the steam destroyed the targeted tissue and …
Phase: NA • Sponsor: Francis Medical Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for tough ovarian cancer: targeted drug shows promise in trial
Disease control CompletedThis study tested a new drug, farletuzumab ecteribulin, which targets a protein found on many ovarian cancer cells. It was compared to standard chemotherapy in 106 women whose ovarian cancer had stopped responding to platinum-based treatments. The goal was to see if the new drug …
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase: PHASE1, PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo therapy targets resistant prostate cancer
Disease control CompletedThis early-stage study tested a new drug, ARV-110, combined with the standard treatment abiraterone in 45 men with metastatic prostate cancer whose PSA levels were rising despite abiraterone alone. The main goals were to check safety and find the best dose. The study is complete,…
Phase: PHASE1 • Sponsor: Arvinas Androgen Receptor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Vaccine-Chemo combo shows promise against spread prostate cancer
Disease control CompletedThis study tested whether adding a prostate cancer vaccine (PROSTVAC) and chemotherapy (docetaxel) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. 74 men with metastatic castration-sensitive prostate cancer took part. …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Double radiation attack shows promise for returning prostate cancer
Disease control CompletedThis study tested whether adding a radioactive drug (radium-223) to standard targeted radiation (SBRT) can delay cancer progression in men whose prostate cancer has returned in a few bone spots but hasn't yet become hormone-resistant. Twelve men participated, receiving either the…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control CompletedThis phase II trial tested whether combining two drugs, pembrolizumab and olaparib, could help people with persistent or recurrent endometrial cancer or carcinosarcoma. The study enrolled 26 participants and looked at how many responded to treatment and what side effects occurred…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for japanese men with tough prostate cancer?
Disease control CompletedThis early-phase study tested a new drug, opevesostat (MK-5684), in 7 Japanese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. This is a first step to se…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New cocktail aims to stall spread of prostate cancer
Disease control CompletedThis large Phase 3 trial tested whether adding the immunotherapy pembrolizumab (Keytruda) to standard hormone therapy (enzalutamide plus ADT) could improve outcomes for men with metastatic hormone-sensitive prostate cancer. Over 1,200 participants were enrolled. The study was unb…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Laser zaps prostate cancer in office procedure
Disease control CompletedThis early study tested a new laser treatment for prostate cancer that can be done in a doctor's office. Ten men with early-stage prostate cancer received focal laser ablation guided by MRI and ultrasound images. The main goal was to see if the procedure is safe and feasible, not…
Phase: EARLY_PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to stop prostate cancer relapse after surgery
Disease control CompletedThis study tested whether adding apalutamide to standard hormone therapy after prostate removal surgery can keep prostate cancer from coming back in high-risk patients. 108 men who had surgery for non-spread prostate cancer took the drug combo for up to 2 years. Researchers check…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy combo shows promise in advanced cervical cancer trial
Disease control CompletedThis phase 3 trial tested whether adding the immunotherapy drug atezolizumab to standard chemotherapy and bevacizumab helps women with advanced, persistent, or recurrent cervical cancer live longer. The study enrolled 410 participants and compared the new combination against the …
Phase: PHASE3 • Sponsor: Grupo Español de Investigación en Cáncer de Ovario • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
One-Time radiation blast shows promise for prostate cancer
Disease control CompletedThis study tested a single, high-dose radiation treatment for men with low-risk or low intermediate-risk prostate cancer. The goal was to see how well the body tolerates this one-time treatment by tracking side effects in the bladder and digestive system within the first 6 months…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail of drugs shows promise for tough prostate cancer
Disease control CompletedThis early-phase trial tested a combination of four drugs—apalutamide, abiraterone, docetaxel, and prednisone—in 16 men with metastatic castrate-resistant prostate cancer, a form of the disease that no longer responds to standard hormone therapy. The main goal was to find a safe …
Phase: PHASE1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Radioactive particles aim to fight ovarian cancer spread
Disease control CompletedThis early-phase trial tested a new treatment called Radspherin for women with ovarian cancer that has returned and spread in the abdomen. Radspherin consists of tiny radioactive particles injected directly into the belly after surgery to remove visible tumors. The study involved…
Phase: PHASE1 • Sponsor: Oncoinvent Solutions AS • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase: PHASE1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control CompletedThis early-phase study tested a new treatment called JNJ-75229414, which uses a patient's own immune cells (T cells) engineered to attack prostate cancer cells. The study involved 15 men with metastatic castration-resistant prostate cancer that had already been treated with other…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Personalized chemo dosing aims to beat tough testicular cancers
Disease control CompletedThis phase 2 trial tested a high-dose chemotherapy regimen called TICE in 101 patients with germ cell tumors that had relapsed or were not responding to standard treatment. The approach uses two cycles of paclitaxel and ifosfamide followed by three cycles of carboplatin and etopo…
Phase: PHASE2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take on HPV cancers in early trial
Disease control CompletedThis study tested a new experimental treatment called HPVST cells in 32 people with HPV-related cancers that had returned or not responded to standard care. The cells are grown from the patient's own blood and trained to attack HPV-infected cancer cells. The goal was to find a sa…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Tiny implants take aim at prostate cancer: a smarter shot?
Disease control CompletedThis study tested a precise radiation implant (brachytherapy) for men with low-risk prostate cancer. Instead of treating the whole prostate, doctors placed radioactive seeds only in the tumor area. The goal was to see if this targeted approach could deliver the right radiation do…
Phase: PHASE2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Prostate cancer radiation showdown: which treatment wins?
Disease control CompletedThis study compared two types of radiation therapy for men with intermediate-risk prostate cancer: standard image-guided external beam radiation (IGRT) versus IGRT plus a high-dose-rate brachytherapy boost. The goal was to see which treatment works better and what side effects oc…
Phase: NA • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill aims to keep endometrial cancer at bay after chemo
Disease control CompletedThis Phase 3 trial tested whether taking the drug selinexor as a maintenance pill after chemotherapy can help delay cancer progression in people with advanced or recurrent endometrial cancer. 263 participants who had responded to initial chemo were randomly assigned to receive ei…
Phase: PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo shrinks prostate tumors before radiation
Disease control CompletedThis study tested a drug combination (abiraterone acetate plus prednisolone and hormone therapy) given before radiation in 45 men with high-risk localized prostate cancer. The goal was to see if the treatment could shrink tumors and lower PSA levels. The approach aims to improve …
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise for tough ovarian cancers
Disease control CompletedThis study tested a combination of two drugs, AZD6738 and olaparib, in 123 women with recurrent ovarian cancer. The goal was to see if the combo is safe and how well it shrinks tumors or delays cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer…
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo therapy shows promise for tough prostate cancer
Disease control CompletedThis study tested whether giving two drugs together—Radium-223 and enzalutamide—is safe for men with advanced prostate cancer that has spread to other parts of the body and is no longer controlled by standard hormone therapy. 45 men took part. The main goal was to track serious s…
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail shows promise for Tough-to-Treat uterine cancer
Disease control CompletedThis phase 2 trial tested a combination of three drugs—rucaparib, bevacizumab, and atezolizumab—in 30 people with recurrent or progressive endometrial cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors or slow the cancer'…
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New cocktail aims to knock out tough prostate cancer
Disease control CompletedThis study tested whether giving three hormone-blocking drugs along with high-dose, precisely targeted radiation could stop very high-risk prostate cancer from coming back. Sixty-four men with aggressive prostate cancer received the treatment. The main goal was to see how many me…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
E-Cigarettes vs. patches: which helps women with cervical dysplasia quit smoking?
Disease control CompletedThis study tested two ways to help women with cervical dysplasia stop smoking: nicotine patches, gum, or lozenges versus electronic cigarettes. Thirty-one women participated for six weeks. The goal was to see if these methods are acceptable and help reduce or stop smoking. It was…
Phase: NA • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Heated chemo wash may stop colorectal cancer spreading in abdomen
Disease control CompletedThis phase 3 trial tested whether a surgical procedure called laparotomy plus heated chemotherapy (HIPEC) could improve outcomes for colorectal cancer patients at high risk of cancer spreading in the abdomen. 150 patients who had already undergone surgery and chemotherapy were ra…
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Microwave zaps prostate tumors with 3D precision
Disease control CompletedThis study tested a new way to treat intermediate-risk prostate cancer using a 3D map to guide microwaves directly to the main tumor. 76 men across Europe received the treatment, and researchers checked if the cancer was gone after 12 months. The goal is to destroy the cancer whi…
Phase: NA • Sponsor: Koelis • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New Antibody-Drug conjugate STRO-002 tested in advanced cancers
Disease control CompletedThis study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deli…
Phase: PHASE1, PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThis early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New chemo drug shows promise for tough testicular cancers
Disease control CompletedThis phase 2 trial tested a chemotherapy drug called cabazitaxel in 34 men with advanced testicular cancer that had already been treated with at least two other chemotherapies. The goal was to see if cabazitaxel could shrink tumors, including those that spread to the brain. Cabaz…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and nec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Triple immunotherapy cocktail shows promise against tough cancers
Disease control CompletedThis study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Immunotherapy combo shows promise in cervical cancer trial
Disease control CompletedThis phase 2 trial tested whether adding the immunotherapy drug atezolizumab to standard chemoradiation helps people with locally advanced cervical cancer. 189 participants received either the combination or standard treatment alone. The goal was to see if the combination delays …
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Collagen mesh may reduce Post-Surgery complications in peritoneal cancer patients
Disease control CompletedThis study tested a special collagen mesh (Surgicoll-Mesh) placed in the abdomen during surgery for cancers that have spread to the lining of the belly. The goal was to see if it could prevent serious problems like bowel blockages, infections, or the need for more surgery. 60 adu…
Phase: NA • Sponsor: Adichunchanagiri Institute of Medical Sciences, B G Nagara • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug plus chemo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Early trial checks safety of experimental cancer drug
Disease control CompletedThis early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New radiation approach aims to tame pituitary tumors with fewer side effects
Disease control CompletedThis study tested a new way of delivering radiation for people with non-secreting pituitary adenomas that came back or remained after surgery. Instead of a single high dose, the radiation was given in five smaller daily doses. The goal was to see if this approach could control tu…
Phase: NA • Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy for tough prostate cancer shows promise in early trial
Disease control CompletedThis early-phase study tested a new combination of two drugs—enzalutamide and relacorilant—in 42 men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check safety and see how the drugs interact in the body. Researchers also…
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New penile implant study shows promise for Men's confidence
Disease control CompletedThis study tested a silicone block placed under the skin of the penis to improve its size, shape, and appearance. It included 40 men who were unhappy with their penile girth or length. The main goal was to check safety and measure changes in size and patient satisfaction.
Sponsor: International Medical Devices, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Diabetes drug metformin may boost chemo for ovarian cancer
Disease control CompletedThis phase II trial tested whether adding metformin, a common diabetes drug, to standard chemotherapy could help control advanced ovarian, fallopian tube, or primary peritoneal cancer. 111 participants received either metformin or a placebo alongside chemotherapy, followed by mai…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a pill keep endometrial cancer at bay? new study tests rucaparib
Disease control CompletedThis study tested whether the drug rucaparib can help keep metastatic or recurrent endometrial cancer from growing. 79 women who had already received chemotherapy took either rucaparib or a placebo pill twice daily. The goal was to see if rucaparib could delay cancer progression …
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Shorter radiation shows promise for prostate cancer control
Disease control CompletedThis study compared two radiation therapy schedules for men with intermediate- or high-risk prostate cancer. One group received fewer, higher-dose radiation sessions (hypofractionated), while the other received standard daily doses. Both groups also received hormone therapy. The …
Phase: NA • Sponsor: Tanta University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Generic cancer pill matches Brand-Name drug in study
Disease control CompletedThis study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…
Phase: NA • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a short hormone course help men with low-risk prostate cancer avoid treatment?
Disease control CompletedThis study looked at whether taking an oral hormone therapy called apalutamide for 6 months could slow down low-risk prostate cancer and delay the need for more aggressive treatments like surgery or radiation. 93 men on active surveillance (watching the cancer without immediate t…
Phase: PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control CompletedThis study tests a new drug called ZN-c3 (azenosertib), either alone or combined with niraparib, in 117 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to find safe doses and see if the drugs can shrink tumors. It is an early-stage trial, s…
Phase: PHASE1, PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New prostate cancer drug tested in small chinese study
Disease control CompletedThis early-phase study tested a new drug called MK-5684 (opevesostat) in 14 Chinese men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The main goals were to check the drug's safety and how the body processes it. Participants took the…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New combo therapy shows promise for advanced uterine cancer
Disease control CompletedThis study tested a combination of two drugs, lenvatinib and pembrolizumab, against standard chemotherapy in 827 people with advanced endometrial cancer that had worsened after initial treatment. The goal was to see if the combo could delay cancer growth and extend life. Results …
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New immunotherapy combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis phase 2 trial tested a combination of two drugs, favezelimab and pembrolizumab (MK-4280A), in 163 people with either a type of skin cancer (cutaneous squamous cell carcinoma) or endometrial cancer. The goal was to see if the treatment could shrink or eliminate tumors. The st…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for women with Hard-to-Treat uterine cancer?
Disease control CompletedThis study tested an experimental drug called ZN-c3 (azenosertib) in 92 women with a rare and aggressive type of uterine cancer that had come back or not responded to standard treatments. The goal was to see if the drug could shrink tumors and to check its safety. The drug is tak…
Phase: PHASE2 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill takes on stomach cancer in first human trial
Disease control CompletedThis study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail shows promise for Hormone-Sensitive uterine cancer
Disease control CompletedThis phase 2 study tested a combination of two drugs, fulvestrant and abemaciclib, in 28 patients with a specific type of uterine cancer that is sensitive to hormones. The goal was to see if the drugs could shrink tumors or stop them from growing. Researchers also tracked side ef…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New cancer combo drug tested in tiny safety study
Disease control CompletedThis early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body h…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Drug holiday or not? sarcoma study tests best strategy
Disease control CompletedThis study looked at 53 adults with advanced soft tissue sarcoma who had stable disease or improvement after 6 cycles of trabectedin. Half continued the drug, while the other half took a break (drug holiday). The goal was to see which approach better delays cancer progression and…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New combo shows promise for tough lymphomas
Disease control CompletedThis study tested adding lenalidomide to a standard chemotherapy regimen (EPOCH-R) in 55 people with aggressive B-cell lymphomas linked to the MYC gene. The goal was to find the best dose and see if the combination improves how long patients live without their cancer getting wors…
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New radiation combo aims to tame prostate cancer with fewer side effects
Disease control CompletedThis study tested a new way to give radiation to men with intermediate-risk prostate cancer. After standard radiation to the prostate and nearby glands, a precise, high-dose boost was added to the tumor. The goal was to improve cancer control while keeping side effects on the bla…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New cancer drug RS-0139 tested in humans for first time
Disease control CompletedThis early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…
Phase: PHASE1 • Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Immune drug rituximab tested to shrink prostate tumors before surgery
Disease control CompletedThis early-phase trial tested whether rituximab, a drug that depletes B cells, could reduce immune cell infiltration in prostate tumors. Eight high-risk prostate cancer patients received four weekly doses before their scheduled prostate removal. The main goal was to see if B-cell…
Phase: EARLY_PHASE1 • Sponsor: Christopher Kane • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for advanced cervical cancer: immune combo shows promise
Disease control CompletedThis study tested a new drug combination (tiragolumab plus atezolizumab) against atezolizumab alone in 172 people with advanced or returning cervical cancer that has a specific marker (PD-L1-positive). The goal was to see if the combination could shrink tumors better. Participant…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo shows promise for resistant ovarian cancer
Disease control CompletedThis study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with ovarian cancer that stopped responding to platinum chemotherapy and had previously taken PARP inhibitors. The goal was to see if the combo could control the cancer for at least 6 months. The…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Engineered immune cells take on HPV cancers
Disease control CompletedThis trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also rec…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo therapy shows promise for Tough-to-Treat cervical cancer
Disease control CompletedThis study tested a combination of an immunotherapy drug (anti-PD-1) and a chemotherapy drug (albumin-bound paclitaxel) in 27 people whose cervical cancer had returned or worsened after standard treatment. The goal was to see if the combination could shrink tumors and help patien…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo shows promise for hard-to-treat ovarian cancer
Disease control CompletedThis study tested a combination of two drugs, apatinib and etoposide, in 35 women with ovarian cancer that had stopped responding to platinum-based chemotherapy. The goal was to see if the combination could shrink tumors or slow disease progression. Participants took the drugs by…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Hormone therapy boost for prostate cancer radiation shows promise
Disease control CompletedThis large phase 3 trial studied 1,538 men with intermediate-risk prostate cancer. It compared dose-escalated radiation therapy alone versus radiation plus short-term (6 months) androgen deprivation therapy (hormone therapy). The goal was to see if adding hormone therapy improves…
Phase: PHASE3 • Sponsor: Radiation Therapy Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Prostate cancer radiation showdown: does adding external beam help?
Disease control CompletedThis study looked at 588 men with intermediate-risk prostate cancer to see if adding external beam radiation to brachytherapy (placing radioactive seeds in the prostate) works better than brachytherapy alone. The goal was to see which approach better controls the cancer over time…
Phase: PHASE3 • Sponsor: Radiation Therapy Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo aims to boost radiation success in aggressive prostate cancer
Disease control CompletedThis Phase 3 trial tested whether adding the drug TAK-700 to standard hormone therapy and radiation could better control high-risk prostate cancer. 239 men participated. The study compared standard treatment (GnRH agonist plus anti-androgen) with an enhanced version that also inc…
Phase: PHASE3 • Sponsor: Radiation Therapy Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Promising drug shows hope for Hard-to-Treat prostate cancer
Disease control CompletedThis study tested a drug called niraparib in 11 men with advanced prostate cancer that was no longer responding to hormone therapy but had recently been treated with platinum chemotherapy. The goal was to see if niraparib could keep the cancer from growing for at least 6 months. …
Phase: PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New radioactive tracer could spot hidden cancers
Diagnosis CompletedThis completed phase 1 trial tested a radioactive imaging agent called [99mTc]Tc-DB8 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help detect tumors using SPECT scans. Researchers also checked for safety and…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
New scan could light up hidden cancers
Diagnosis CompletedThis completed phase 1 study tested a new radioactive imaging agent called 99mTc-RM26 in 10 people with prostate or breast cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors using SPECT scans. Researchers also checked for safety and …
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New scan could spot hidden cancers
Diagnosis CompletedThis completed Phase 1 study tested a new radioactive imaging agent called [123I]I-DARPIN-Ec1 in 10 people with lung or ovarian cancer. The goal was to see how the agent spreads in the body and whether it can help spot tumors on SPECT scans. Researchers compared the new scan resu…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New imaging agent could sharpen prostate cancer detection
Diagnosis CompletedThis completed Phase 1 study tested a new radioactive tracer called [99mTc]Tc-BQ0413 in 10 men with prostate cancer. The tracer was injected once, and SPECT scans were taken over 24 hours to see where it goes in the body and how safe it is. The goal is to develop a better imaging…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:02 UTC
-
New imaging agent targets LRRC15 to sharpen cancer diagnosis
Diagnosis CompletedThis study tests a special SPECT imaging agent that seeks out a protein called LRRC15, found on many aggressive cancers like pancreatic, breast, lung, and brain tumors. The goal is to see if this scan can help doctors diagnose and stage these cancers more accurately. Healthy volu…
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
New blood test aims to spot prostate cancer cells earlier
Diagnosis CompletedThis study tested a new blood test called EPISPOT to find prostate cancer cells in the blood of 361 men with localized prostate cancer before they received any treatment. The goal was to see if this test could predict remission better than an existing test called CellSearch. The …
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Glow-in-the-Dark dye could help surgeons spot hidden prostate cancer
Diagnosis CompletedThis completed Phase 2 trial tested an imaging dye called Cytalux (pafolacianine) in 9 men with prostate cancer. The dye is injected before surgery and makes cancer cells glow under near-infrared light, helping surgeons see and remove all cancerous tissue during prostate removal.…
Phase: PHASE2 • Sponsor: Indiana University • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
Pee test for cervical cancer? study checks if women like it
Diagnosis CompletedThis study looked at whether women would be willing to collect their own urine sample for cervical cancer screening instead of a traditional swab. 173 women aged 31-49 at a French hospital tried it and answered questions about their experience. The goal was to see how acceptable …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Temperature-Sensing MRI could sharpen prostate cancer detection
Diagnosis CompletedThis study tested a new MRI method that measures temperature changes in the prostate. The goal is to help doctors find cancer more accurately and guide laser treatments. Researchers scanned 70 men who already needed an MRI for prostate cancer diagnosis. The focus was on checking …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
AI and PET scans join forces to grade cancer without a biopsy
Diagnosis CompletedThis completed study tested whether combining PET/MRI scans with machine learning could better assess how aggressive prostate cancer and other solid tumors are. Researchers enrolled 50 adults with prostate cancer, liver cancer, brain tumors, or kidney cancer. The goal was to see …
Sponsor: Ciprian Catana, MD, PhD • Aim: Diagnosis
Last updated Jun 27, 2026 12:37 UTC
-
AI takes on prostate cancer detection: could it replace the radiologist?
Diagnosis CompletedThis study tested an AI software called Quantib Prostate to see if it can detect prostate cancer on MRI scans as accurately as expert radiologists. Researchers looked at 200 men who had prostate MRIs and biopsies. The AI's readings were compared to the radiologist's readings, usi…
Sponsor: IRCCS San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 12:34 UTC
-
Prostate fluid particles may hold key to smarter cancer detection
Diagnosis CompletedThis study looked at tiny particles called extracellular vesicles (EVs) found in prostate fluid from 100 men. The goal was to find unique molecular signatures that could help tell aggressive prostate cancer from slow-growing or benign conditions. Researchers used advanced techniq…
Sponsor: IRCCS San Raffaele • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Dogs on the scent: can they sniff out cancer?
Diagnosis CompletedThis study tested whether specially trained dogs can identify breast, lung, prostate, or colorectal cancer by sniffing breath samples collected on masks. Over 1,300 people provided breath samples before their regular cancer screening or biopsy. The dogs' results were compared to …
Sponsor: SpotitEarly • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Which PET scan is better at spotting prostate cancer?
Diagnosis CompletedThis study tested two different radioactive tracers (68Ga-RM2 and 68Ga-PSMA-617) used in PET/CT scans to see which one better detects prostate cancer in men scheduled for prostate removal surgery. Twenty-two men with low, intermediate, or high-risk prostate cancer received both s…
Phase: PHASE2 • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Could a simple pad replace invasive biopsies for uterine cancer?
Diagnosis CompletedThis study tested a special pad (PadKit™) worn for 4-6 hours to collect cells shed from the uterus. Researchers wanted to see if the pad could gather enough cells to tell the difference between normal tissue, precancerous changes, and cancer. 80 women scheduled for surgery (some …
Phase: NA • Sponsor: Hackensack Meridian Health • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Which PET tracer shows prostate cancer recurrence better?
Diagnosis CompletedThis study compared two radioactive tracers, piflufolastat (18F) and flotufolastat (18F), used in PET scans to detect prostate cancer that has returned after surgery. The main goal was to see which tracer produces less radioactivity in the bladder, which can interfere with image …
Phase: PHASE4 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jun 27, 2026 12:31 UTC
-
AI matches expert radiologists in spotting prostate cancer
Diagnosis CompletedThis study tested whether an artificial intelligence (AI) system could help find prostate cancer on MRI scans. 365 men who needed a prostate biopsy had their MRI images reviewed by both the AI and by senior radiologists. Doctors then performed targeted biopsies on any suspicious …
Phase: NA • Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New study weighs safer prostate biopsy methods
Diagnosis CompletedThis study looked at two methods of taking prostate tissue samples to diagnose cancer: one through the rectum and one through the skin between the scrotum and anus. Researchers wanted to see which method causes fewer infections and less bleeding. 101 men with suspected prostate c…
Phase: NA • Sponsor: Elsan • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Could a vaginal fluid test spot ovarian cancer earlier?
Diagnosis CompletedThis study looked at whether fluid collected from behind the vagina (culdocentesis) can help diagnose ovarian cancer. Researchers measured tumor markers CA-125 and HE4 in the fluid of 52 women scheduled for surgery. They also checked a urine sample for estrogen ratios. The goal w…
Sponsor: Southern Illinois University • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
New imaging showdown: can PSMA PET/CT beat MRI for prostate cancer detection?
Diagnosis CompletedThis study looked at 60 men who had a prostate biopsy to check for cancer. It compared two imaging methods used to guide the biopsy: the standard multiparametric MRI and a newer scan called Ga-68 PSMA PET/CT. The goal was to see which method better finds aggressive prostate cance…
Sponsor: Fatih Sultan Mehmet Training and Research Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
New scanner could help surgeons spot Left-Behind cancer Mid-Operation
Diagnosis CompletedThis study tested a new type of PET-CT scanner that can scan a tumor right after it is removed from the body. Patients with prostate or head and neck cancer received a small amount of radioactive tracer before surgery, which sticks to cancer cells. After removal, the specimen was…
Phase: NA • Sponsor: University Hospitals Coventry and Warwickshire NHS Trust • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Could a 'Negative' HPV test miss warning signs? new study investigates
Diagnosis CompletedThis study looked at 45 patients whose HPV tests came back negative but had a late signal in the raw data. Researchers wanted to see if these late signals might actually indicate early cervical cell changes. By comparing different lab methods, they aim to improve how we interpret…
Sponsor: University Hospital, Brest • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
New Light-Based scan could spot prostate cancer faster
Diagnosis CompletedThis study tested a new imaging technique called Full Field Optical Coherence Tomography (FFOCT) to see if it can detect prostate cancer in biopsy samples as well as standard microscope analysis. Researchers compared FFOCT results to the usual pathology exam in 91 men with elevat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
New scan spots prostate cancers standard MRI misses
Diagnosis CompletedThis study tested whether a high-resolution PET-MRI scan using a prostate-specific tracer (18F-PSMA) can find cancers that standard MRI might miss. 62 men with prostate cancer considering focal therapy or surgery received both scans, and results were checked with biopsies. The go…
Phase: PHASE2 • Sponsor: Alessandro D'Agnolo • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New Self-Test could revolutionize cervical cancer screening
Diagnosis CompletedThis study tested a new way to screen for cervical cancer using samples women collect themselves at home. Researchers wanted to see if a test that looks at DNA changes in HPV could better identify who truly needs follow-up care. About 294 women participated, and the goal was to m…
Sponsor: George Washington University • Aim: Diagnosis
Last updated Jun 27, 2026 09:10 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
Culturally tailored program aims to boost cervical cancer screening in black women
Prevention CompletedThis study tests a program called 'Health is Wealth: A Cervical Health Program' designed to encourage cervical cancer screening among African American and Sub-Saharan African immigrant women. Participants attend a two-hour educational session and receive an HPV self-sampling kit …
Phase: NA • Sponsor: Adebola Adegboyega • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Can removing ovaries prevent cancer in High-Risk women? new study investigates
Prevention CompletedThis study followed 40 women at high genetic risk for ovarian cancer due to BRCA mutations or strong family history. One group chose to have their ovaries and fallopian tubes removed to prevent cancer, while the other group opted for regular CA-125 blood tests every 3 months to c…
Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 27, 2026 13:05 UTC
-
Game changers: peer advocates aim to prevent cervical cancer in uganda
Prevention CompletedThis study tested a program called Game Changers for Cervical Cancer Prevention (GC-CCP) in Uganda. It trained women who had already been screened to encourage their friends and family to get screened too. The trial involved 936 participants and compared the program to usual care…
Phase: NA • Sponsor: RAND • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Can the HPV vaccine stop cervical abnormalities from returning after surgery?
Prevention CompletedThis study looked at whether giving the Gardasil 9 HPV vaccine to women at the same time as surgery for abnormal cervical cells (CIN) can help clear the virus and prevent future infections. About 1,100 women aged 18-55 took part. The goal was to see if the vaccine reduces the cha…
Phase: PHASE3 • Sponsor: Imperial College London • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
At-Home HPV test kits could boost cervical cancer screening in Hard-to-Reach women
Prevention CompletedThis study tested whether offering a vaginal self-sampling kit directly to women aged 50-65 who had not had a cervical smear in over three years would increase screening participation. Women received a kit to use at home and mail to a lab for HPV testing. The goal was to see how …
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
New screening strategy aims to prevent uterine cancer in High-Risk women
Prevention CompletedThis study tested a two-step screening process to find postmenopausal women at higher risk for endometrial cancer. Those identified as high-risk received a hormone challenge test and, if positive, standard care plus a lifestyle program. The goal was to see if this approach is pra…
Phase: PHASE4 • Sponsor: University of British Columbia • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
At-Home HPV test could save lives in underserved asian women
Prevention CompletedThis completed trial enrolled 797 Asian American women (Korean, Vietnamese, Chinese) aged 30-65 who were overdue for cervical cancer screening. All participants received community education and help scheduling a clinic screening. Half also got an HPV self-sampling kit to use at h…
Phase: NA • Sponsor: Fox Chase Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Chill out: ice therapy may cool down prostate biopsy pain
Symptom relief CompletedThis study tests whether placing ice inside the rectum before a prostate biopsy can lower pain, anxiety, stress hormone levels, and complications like bleeding. About 84 men having their first prostate biopsy will either receive standard care or ice application. The goal is to se…
Phase: NA • Sponsor: Mersin University • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
Could a tiny dose of this drug help men with prostate cancer avoid surgery?
Symptom relief CompletedThis study tested whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, could lower PSA levels in 34 men with early-stage prostate cancer. The goal was to see if the drug blocks testosterone's effect on cancer growth. If it works, it might o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Remote strength training aims to boost endometrial cancer survivorship in rural areas
Symptom relief CompletedThis study tests a 10-week, remotely supervised strength training program for endometrial cancer survivors living in rural or underserved areas. The goal is to see if the program is practical and helps improve physical function and quality of life. Participants exercise twice a w…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New drug M701 aims to stop Cancer-Related fluid buildup without drains
Symptom relief CompletedThis study tested a drug called M701, given directly into the belly, combined with standard cancer therapy, for people with malignant ascites (fluid buildup) from stomach, colon, or ovarian cancer. The goal was to see if M701 could delay the need for fluid drainage and improve su…
Phase: PHASE2 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Beauty treatments ease cancer pain and anxiety, study finds
Symptom relief CompletedThis study tested whether professional socio-aesthetics (specialized beauty and well-being care) can improve quality of life, reduce pain, and ease anxiety in adults undergoing chemotherapy for lung, breast, colon, or prostate cancer. 400 participants were randomly assigned to re…
Phase: NA • Sponsor: Centre Hospitalier de Valence • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Smartphone app eases fear before prostate surgery, study finds
Symptom relief CompletedThis study tested whether a mobile app that teaches patients about prostate surgery can improve their experience. 68 patients were split into two groups: one used the app, the other received standard care. Researchers measured anxiety, fear, pain, and satisfaction before and afte…
Phase: NA • Sponsor: Tarsus University • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Shorter steroid regimen may prevent chemo allergies just as well
Symptom relief CompletedThis study tested three ways of giving the steroid dexamethasone to prevent allergic reactions from the chemotherapy drug paclitaxel in 90 women with breast or gynecologic cancer. One group took oral dexamethasone the night before and morning of treatment, another got it intraven…
Phase: PHASE3 • Sponsor: Loma Linda University • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
New therapy aims to ease emotional toll of testicular cancer in young latino men
Symptom relief CompletedThis pilot study tested a 6-session therapy called Goal-Focused Emotion Regulation Therapy (GET) in 35 young Latino testicular cancer survivors aged 18-39. The therapy helps participants set goals, manage emotions, and find meaning after cancer. Researchers measured anxiety, depr…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New nursing approach cuts clots and swelling after cervical cancer surgery
Symptom relief CompletedThis study tested whether a special nursing plan (called ERAS) could help women recover after surgery for cervical cancer. 160 women were split into two groups: one got the ERAS nursing plan, the other got standard care. The goal was to see if the ERAS plan could lower the risk o…
Phase: NA • Sponsor: People's Hospital of Xinjiang Uygur Autonomous Region • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Online program helps ovarian cancer survivors feel better
Symptom relief CompletedThis study tested a web-based program to improve quality of life and reduce stress in ovarian cancer survivors. 326 women participated, comparing a mindfulness program to a healthy lifestyle program. The goal was to see if the online programs could help with stress, anxiety, mood…
Phase: NA • Sponsor: Susan Lutgendorf • Aim: Symptom relief
Last updated Jun 27, 2026 12:39 UTC
-
New hope for better sleep after gynecologic cancer: behavioral interventions show promise
Symptom relief CompletedThis study tested three behavioral approaches—sleep restriction, stimulus control, and systematic light exposure—to help gynecologic cancer survivors who have trouble sleeping. 78 participants completed the program, and researchers measured changes in sleep quality and daytime im…
Phase: NA • Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Cancer Survivors' sex drive gets a boost: bupropion shows promise
Symptom relief CompletedThis study tested whether bupropion, a medication that affects brain chemicals, can improve low sexual desire in women who have had breast or gynecologic cancer. About 230 women took either bupropion or a placebo pill for 9 weeks. The main goal was to see if their self-reported s…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
Hypnosis before hysterectomy: a new way to ease cancer surgery nerves?
Symptom relief CompletedThis study looked at whether a one-hour hypnosis session, done 5 to 15 days before a hysterectomy for pelvic gynecological cancer, could lower anxiety around the time of surgery. Twenty-nine women participated, and the hypnosis was guided by a trained nurse. The main goal was to …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Can a longer overnight fast help men on prostate cancer treatment?
Symptom relief CompletedThis small pilot study tested a 3-month program where men with prostate cancer on hormone therapy were encouraged to fast for 12 to 16 hours each night, supported by weekly coaching calls and text messages. The 40 participants found the program feasible and satisfying, with some …
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Vitamin cocktail may shrink fibroids, reduce surgery need
Symptom relief CompletedThis study tested a 3-month treatment with a combination of vitamin D, green tea extract (EGCG), vitamin B6, and D-Chiro-inositol in 108 women with uterine fibroids who were planning surgery. The goal was to see if the supplement could ease symptoms and possibly help some women a…
Phase: NA • Sponsor: Universita di Verona • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Massage therapy may ease painful sex after gynecological cancer
Symptom relief CompletedThis study tested whether a special perineal massage technique could reduce pain during sex and vaginal tightness in women treated for gynecological cancer. 35 women received either the massage or standard dilator treatment over ten sessions. The goal was to see if the massage im…
Phase: NA • Sponsor: University of Alcala • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
Can a simple dilator boost sexual health after cancer treatment?
Symptom relief CompletedThis study looked at whether using a vaginal dilator for 12 weeks helps women who had brachytherapy for cervical cancer. Researchers measured sexual function, self-compassion, and quality of life in 80 participants at three time points. The goal was to see if this simple tool can…
Phase: NA • Sponsor: Istanbul Aydın University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
New study tests best method to cut bleeding in fibroid surgery
Symptom relief CompletedThis study looked at 120 women having open surgery for uterine fibroids to see which method best reduces bleeding. Doctors compared using a tourniquet, clamping the uterine artery, or no compression at all. The goal is to find the safest way to control blood loss and improve reco…
Phase: NA • Sponsor: Yuzuncu Yil University • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Warm water on feet may ease Pre-Surgery jitters
Symptom relief CompletedThis study tested whether soaking feet in warm water for 20 minutes before pituitary tumor surgery helps patients feel less anxious and keeps vital signs stable. 100 adults were enrolled, with one group receiving the foot bath and the other standard care. Researchers measured anx…
Phase: NA • Sponsor: Trakya University • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
New study tests better pain control during brain surgery
Symptom relief CompletedThis study looked at two ways to numb a nerve bundle in the face during pituitary gland surgery. The goal was to see which method reduces the amount of anesthesia needed during the operation. Sixty adults having this type of surgery took part. The results help doctors choose the …
Phase: NA • Sponsor: Donia Hany Saad • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New vaginal surgery technique may reduce pain after hysterectomy
Symptom relief CompletedThis study compared two types of minimally invasive hysterectomy: vNOTES (done through the vagina) and conventional laparoscopic hysterectomy (done through small belly cuts). About 90 women having hysterectomy for non-cancer reasons took part. The goal was to see which method cau…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Walking your way through chemo: study tests if steps keep treatment on track
Symptom relief CompletedThis study tested whether a simple walking program, guided by a fitness tracker, could help cancer patients tolerate their chemoradiotherapy without missing treatments. 166 adults with brain, head and neck, lung, gastrointestinal, or cervical cancer participated. Patients were gi…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Exercise eases chemo fatigue in testicular cancer patients
Symptom relief CompletedThis study tested whether an 8-week program of strength, endurance, and aerobic exercise could reduce fatigue in men with testicular germ cell cancer undergoing chemotherapy. Twenty men participated, with half doing the exercise program and half receiving usual care. The goal was…
Phase: NA • Sponsor: University of Malaga • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Home workouts help cancer patients feel better during pandemic
Symptom relief CompletedThis study tested whether an online exercise and education program could help cancer patients and survivors feel better during the COVID-19 pandemic. Thirty adults with metastatic breast or gynecological cancer, or breast cancer survivors, took part. The program aimed to reduce f…
Phase: NA • Sponsor: University of Malaga • Aim: Symptom relief
Last updated Jun 27, 2026 12:05 UTC
-
Can a VR headset calm chemo anxiety? new study tests hypnosis in prostate cancer patients
Symptom relief CompletedThis study tested whether using virtual reality hypnosis before chemotherapy infusions could lower anxiety in men with metastatic prostate cancer. Fifty-three patients were randomly assigned to either receive the VR hypnosis session or standard care before each docetaxel infusion…
Phase: NA • Sponsor: Saint-Gregoire Private Hospital Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
New program helps men fight prostate cancer side effects
Symptom relief CompletedThis study tested a program to help men prepare for and manage side effects from prostate cancer treatments like surgery or radiation. The program used daily texts and emails, plus support from other men, to encourage healthy habits before treatment. The goal was to reduce distre…
Phase: NA • Sponsor: Nova Scotia Health Authority • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Can a nurse and an app improve life after gynecologic cancer?
Symptom relief CompletedThis study tested a new way to follow up with gynecologic cancer survivors. Instead of seeing a doctor every time, patients saw a nurse at every other visit and used a smartphone app to help manage their health. The goal was to see if this approach improved self-management skills…
Phase: NA • Sponsor: Sorlandet Hospital HF • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Grape extract shows promise for easing fatigue in prostate cancer patients
Symptom relief CompletedThis study tested whether a supplement made from muscadine grapes could reduce fatigue and improve quality of life in 106 men with prostate cancer who were already receiving hormone therapy (androgen deprivation therapy). Participants took either the grape extract or a placebo fo…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Pre-Surgery bootcamp boosts recovery for prostate cancer patients
Symptom relief CompletedThis study tested whether a prehabilitation program—including exercise, nutrition advice, and education—before robotic prostate surgery helps men regain quality of life more quickly. One hundred men with localized prostate cancer participated. The goal was to see if preparing the…
Phase: NA • Sponsor: Hospital Clinic of Barcelona • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Prostate cancer patients weigh in: which chemo is easier to tolerate?
Symptom relief CompletedThis study looked at whether men with metastatic prostate cancer prefer cabazitaxel or docetaxel as their first chemotherapy. 195 patients tried both drugs in sequence and then stated their preference. The goal is to see if side effects like nerve damage or fatigue influence choi…
Phase: PHASE3 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Acupuncture before surgery may steady blood pressure in hysterectomy patients
Symptom relief CompletedThis small pilot study looked at whether acupuncture given twice before surgery could help stabilize blood pressure in women having their uterus removed (total laparoscopic hysterectomy) for fibroids. Thirty-five adult patients received acupuncture before the operation, and resea…
Phase: NA • Sponsor: Ilsan Cha hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New smartphone app aims to ease cancer symptoms for women
Symptom relief CompletedThis study developed and tested a smartphone app to help Taiwanese women with gynecological cancer learn about their condition and manage symptoms. 67 women used the app, which included a chatbot and educational content. Researchers measured changes in symptom distress, informati…
Phase: NA • Sponsor: Chang Gung Memorial Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can pelvic PT help cancer survivors regain sexual health?
Symptom relief CompletedThis study looked at whether a 10-week pelvic physical therapy program is practical for gynecologic cancer survivors who have sexual problems. Twenty survivors were enrolled to see if they could stick with the program and if it improved their sexual function and quality of life. …
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can brain training ease 'Chemo Brain' in gynecologic cancer survivors?
Symptom relief CompletedThis study tested a home-based cognitive training program called BrainHQ in 60 women with gynecologic cancers who had memory or thinking problems after chemotherapy. Participants used the app for about 2.5 hours per week for 10 weeks. The goal was to see if the program was practi…
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Simple drain may stop Post-Surgery shoulder pain
Symptom relief CompletedThis study tested whether placing a small drain in the belly to remove leftover gas after laparoscopic gynecologic surgery reduces shoulder and rib pain. 202 women were randomly assigned to get the drain or standard manual gas release. The goal was to see if fewer women in the dr…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Could a common painkiller combo ease cancer treatment pain?
Symptom relief CompletedThis study tested whether adding ketoprofen to standard paracetamol (acetaminophen) can better control pain in patients receiving brachytherapy for cervical or upper airway/digestive tract cancers. Sixty-eight adults were randomly assigned to receive either paracetamol alone or p…
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Music eases anxiety during prostate cancer therapy, study finds
Symptom relief CompletedThis study tested whether listening to music during radionuclide treatment helps prostate cancer patients feel less anxious and distressed. Sixty men were split into two groups: one listened to their choice of instrumental music through headphones during treatment, while the othe…
Phase: NA • Sponsor: Dokuz Eylul University • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
New support program aims to ease cancer Patients' transition home from hospital
Symptom relief CompletedThis study tested a program called BOLSTER, designed to give extra support to people with gynecologic or gastrointestinal cancers and their caregivers after a hospital stay. The goal was to see if the program was practical and well-liked. 121 adults with complex care needs took p…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Needles vs. night sweats: can acupuncture cool prostate cancer side effects?
Symptom relief CompletedThis small pilot study tested whether acupuncture could help reduce hot flashes and night sweats in men with prostate cancer who are on hormone therapy. Twelve men received acupuncture sessions, and researchers measured how well the treatment was accepted and whether symptoms imp…
Phase: NA • Sponsor: University College Cork • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Scientists uncover genetic secrets behind rare hormone disorders
Knowledge-focused CompletedThis study looked at nearly 1,400 people with rare conditions like PPNAD, Carney Complex, and Peutz-Jeghers syndrome. The goal was to find the genetic causes and link them to specific symptoms. Researchers used clinical exams and genetic testing to better understand how these dis…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Protein 'Fingerprint' blood test could warn of ovarian cancer return
Knowledge-focused CompletedThis study looks at proteins in the blood of women with ovarian, peritoneal, or fallopian tube cancer who are in remission. The goal is to find a protein pattern, or 'fingerprint,' that signals when the cancer might come back. Researchers followed 119 women with stage III or IV c…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a quick chat with a radiotherapy tech ease cancer patients' anxiety?
Knowledge-focused CompletedThis study looked at whether having a special consultation with a radiotherapy technician (called a manipulator) helps cancer patients feel more informed about their treatment. Researchers enrolled 308 adults with various cancers who were getting radiation therapy. They compared …
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Enzyme-HPV link in cervical disease explored
Knowledge-focused CompletedThis study looked at how certain enzymes called matrix metalloproteinases (MMPs) and their inhibitors relate to human papillomavirus (HPV) in cervical dysplasia and cancer. Researchers collected tissue and cell samples from 216 women with different stages of cervical lesions. The…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Blood test may predict cancer spread in women
Knowledge-focused CompletedThis completed study looked at whether a simple blood test (liquid biopsy) can help track breast, ovarian, and endometrial cancers. Researchers analyzed circulating tumor cells in 150 women to see if these cells could predict the risk of cancer spreading or how well treatment wor…
Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Ports may offer easier way to deliver prostate cancer drug
Knowledge-focused CompletedThis study tested whether Pluvicto, a radioactive drug for prostate cancer, can be safely given through a permanently implanted port (TIVAP) instead of a standard IV. Researchers measured if any drug got stuck in the port in 107 patients. The goal was to see if using the port is …
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Lab study tests antibody that could unlock immune attack on liver cancer
Knowledge-focused CompletedThis completed study looked at a new antibody called anti-SIRPα as a potential immunotherapy for liver cancer. Researchers used blood and tissue samples from 30 liver cancer patients to see how the antibody affects immune cells. The goal was to understand whether blocking the SIR…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
No antibiotics before prostate biopsy? new study checks safety
Knowledge-focused CompletedThis study looked at whether it is safe to skip antibiotics before a prostate biopsy. Researchers followed 1753 men who had a biopsy through the perineum (the area between the scrotum and anus). They compared infection rates in those who did not get antibiotics to existing data f…
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Phone calls or brochures? study finds best way to get cancer survivors genetic help
Knowledge-focused CompletedThis study looked at two ways to help breast and ovarian cancer survivors get genetic counseling: a mailed brochure or a phone call with a health coach. About 668 women took part. The goal was to see which method led more people to actually get genetic counseling or testing. The …
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Blood test score may guide ovarian cancer treatment decisions
Knowledge-focused CompletedThis study looks at whether a score called KELIM can predict how well ovarian cancer patients respond to maintenance treatment with PARP inhibitors after initial chemotherapy. Researchers will analyze data from 243 patients who took part in the PAOLA-1 trial. If KELIM proves usef…
Sponsor: ARCAGY/ GINECO GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New imaging comparison could improve prostate cancer monitoring
Knowledge-focused CompletedThis completed study looked at 80 patients with advanced prostate cancer that had stopped responding to chemotherapy. All patients received a radioactive drug called 177Lu-PSMA-617. Researchers compared two types of scans—PET and SPECT—to see which better tracks changes in tumor …
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New radiation approach targets multiple tumors at once in early trial
Knowledge-focused CompletedThis early-phase trial tested a precise, high-dose radiation technique called stereotactic body radiotherapy (SBRT) in 42 patients with breast, lung, or prostate cancer that had spread to several places in the body. The main goal was to find the safest dose and check for side eff…
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can survivor stories get more people screened for cancer?
Knowledge-focused CompletedThis study tested whether a short video featuring cancer survivors and local leaders could encourage more people in rural Tamil Nadu to get screened for oral, breast, and cervical cancer. Over 1,200 adults aged 30-59 who had not been screened recently were randomly assigned to se…
Phase: NA • Sponsor: International Agency for Research on Cancer • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
900 Men's quality of life checked years after prostate cancer diagnosis
Knowledge-focused CompletedThis study looks at how prostate cancer and its treatment affect quality of life three years after diagnosis. Researchers compared 900 men with prostate cancer to cancer-free men of the same age. The goal is to understand what life is like after treatment and whether patients ret…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
AI-powered PET scans may predict prostate cancer aggressiveness before surgery
Knowledge-focused CompletedThis study looks at whether a special type of PET scan, using two different tracers, can help predict how aggressive a person's prostate cancer is before surgery. Researchers will use computer models to analyze the scan images and compare the results with standard biopsy and surg…
Sponsor: Xiangya Hospital of Central South University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Which prostate cancer drug is kinder to your brain? new study aims to find out
Knowledge-focused CompletedThis study looked at how two prostate cancer drugs, darolutamide and enzalutamide, affect thinking and memory in men with advanced prostate cancer. About 111 men took one of the two drugs and completed computer-based cognitive tests over time. The goal was to see if one drug caus…
Phase: PHASE2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Texts and nudges may help more people get cancer genetic testing
Knowledge-focused CompletedThis study tested three types of messages to encourage genetic testing in 1,283 people at risk for hereditary breast and ovarian cancer. Participants received an electronic health record message, then a text message, then a doctor's reminder if needed. The goal was to see which a…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study probes how pelvic cancer strains Couples' intimacy
Knowledge-focused CompletedThis study followed 40 women with cervical, uterine, or ovarian cancer to see how their relationship and sexual communication changed from diagnosis to 3 months after treatment. Participants filled out questionnaires about their sexual activity, desire, and discomfort. The goal w…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
New study reveals how brain scans predict surgery outcomes for pituitary tumors
Knowledge-focused CompletedThis study looked at 49 people with masses in the sellar region of the brain (near the pituitary gland). Researchers compared MRI scans before surgery with the final diagnosis after surgery to see how well imaging predicts the type of tumor. The goal was to improve diagnosis and …
Sponsor: Arab Board of Neurosurgery • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Ovarian cancer genetics under the microscope: no treatment, just knowledge
Knowledge-focused CompletedThis study looked at 1,500 women with advanced ovarian, peritoneal, or fallopian tube cancer to see how genetic changes in their tumors relate to how the disease progresses. Researchers collected tumor samples and medical data to find links between DNA abnormalities and outcomes …
Sponsor: ARCAGY/ GINECO GROUP • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Nurse navigators boost cervical cancer screening in study
Knowledge-focused CompletedThis study tested whether a nurse navigation program—including education, counseling, and WhatsApp follow-up—could encourage more women aged 30-65 to get screened for cervical cancer. 80 women who were not regularly screened took part. The program aimed to improve their understan…
Phase: NA • Sponsor: TURKAN OZDAS • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
AI learns from 14,000 prostate scans to spot aggressive cancers
Knowledge-focused CompletedThis study created a massive, secure database of over 14,000 prostate MRI scans from men with or suspected of having prostate cancer. Researchers used this data to train artificial intelligence (AI) models to better tell apart slow-growing from aggressive cancers, predict if canc…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
New study checks drug safety for prostate cancer patients
Knowledge-focused CompletedThis study looked at how an experimental drug called SHR3680 affects the way the body processes three other common drugs: digoxin, rosuvastatin, and metformin. Thirty-six men with prostate cancer took SHR3680 along with these drugs to see if there were any interactions. The goal …
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Herbal supplement tested for safety in prostate cancer – no cure expected
Knowledge-focused CompletedThis early-stage study tested the safety of a single dose of an Angelica herbal supplement (AGN-Cogni.Q) in 12 men aged 40 and older with prostate cancer. Researchers checked heart health and blood tests for any side effects, and measured how the supplement's compounds move throu…
Phase: PHASE1 • Sponsor: Milton S. Hershey Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Family study aims to unlock secrets of hereditary breast and ovarian cancer
Knowledge-focused CompletedThis completed study enrolled 377 individuals and families with a high risk of breast or ovarian cancer due to known or suspected genetic factors. Researchers collected medical records, questionnaires, and biological samples to better understand the disease's natural history and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists hunt for testicular cancer genes in families
Knowledge-focused CompletedThis study aims to understand why testicular cancer sometimes runs in families. Researchers will collect DNA samples and medical information from about 750 people in families with multiple cases of testicular cancer. No treatment is given; the goal is to find genes that increase …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Stiffness check could boost fibroid treatment success
Knowledge-focused CompletedThis study looked at whether measuring the stiffness of uterine fibroids can help predict how well they respond to a non-invasive treatment called MR-HIFU. Forty women with symptomatic fibroids were enrolled. The goal was to improve patient selection so that only those likely to …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Glow-in-the-Dark antibody could help surgeons spot prostate cancer
Knowledge-focused CompletedThis early-phase trial tested a fluorescent antibody that attaches to prostate cancer cells. Seven men with moderate- to high-risk prostate cancer received the antibody before robotic prostate removal surgery. The goal was to see if the glowing antibody could help surgeons identi…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
AI learns to spot cancer pain from faces and voices
Knowledge-focused CompletedThis study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Faith-based workshops aim to boost cancer screening in muslim women
Knowledge-focused CompletedThis study tested whether a two-hour, peer-led workshop with religious messages could encourage Muslim women in North East England and Scotland to get screened for breast, bowel, and cervical cancer. 169 women aged 25-74 who were not up-to-date with all eligible screenings took p…
Phase: NA • Sponsor: University of Sunderland • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Can less anesthesia gas be better for robotic prostate surgery?
Knowledge-focused CompletedThis study looked at two ways of giving anesthesia during robotic prostate removal surgery. One method used a low flow of gas (1 liter per minute) and the other used a normal flow (3 liters per minute). The goal was to see which one is better for breathing, heart function, and co…
Sponsor: Ankara City Hospital Bilkent • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:39 UTC
-
Real-World data on ovarian cancer treatments collected in russia
Knowledge-focused CompletedThis study looked at how doctors in Russia treat a specific type of ovarian cancer called HRD-positive. Researchers collected information from 414 patients to understand what treatments they received and how they fared. The goal was to describe real-world practice, not to test a …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
New ultrasound technique could sharpen prostate cancer detection
Knowledge-focused CompletedResearchers at Stanford University tested a new micro-ultrasound device to see if it can more accurately find and outline prostate cancer. The study involved 95 men scheduled for biopsy or prostate removal. The ultrasound images were compared with standard pathology results to he…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Massive cancer registry tracks genetic Testing's Real-World impact
Knowledge-focused CompletedThis completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Prostate cancer gene hunt could spot relapse early
Knowledge-focused CompletedThis study looked at genetic changes in prostate cancer samples from 84 men who had surgery. The goal was to find DNA markers that could predict if the cancer would come back or spread. By identifying these markers, doctors may one day better tailor follow-up care and treatment f…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
PET/CT scans may sharpen cancer Follow-Up decisions
Knowledge-focused CompletedThis study looked at whether a special PET/CT scan, done within two months after treatment, helps doctors make better decisions for patients with advanced cervical cancer. Researchers compared what doctors would decide without the scan versus with it. The study involved 40 patien…
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
New study aims to fix lack of diversity in cancer trials
Knowledge-focused CompletedThis completed study looked at ways to increase diversity in cancer clinical trials, focusing on breast, liver, and prostate cancers. Researchers worked with communities, doctors, and scientists in New York City to find better ways to include people of color and underserved group…
Phase: NA • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Black raspberries under the microscope for prostate cancer prevention
Knowledge-focused CompletedThis early-phase trial studied how compounds from black raspberries are absorbed and processed in 60 men with prostate cancer who were scheduled for surgery. Participants ate a black raspberry confection and followed a special diet before surgery. The goal was not to treat cancer…
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New digital platform aims to break the silence around hereditary cancer in families
Knowledge-focused CompletedThis study tested a digital health platform to help people with a hereditary risk of breast and ovarian cancer share their genetic test results with family members. Researchers worked with 128 participants in Switzerland and Korea to see if the tool reduced distress and improved …
Phase: NA • Sponsor: University of Basel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Prostate cancer mystery: why do two top scans see different tumors?
Knowledge-focused CompletedThis study looked at 30 men with prostate cancer to understand why MRI and PSMA-PET scans sometimes spot different tumors. Researchers used stored tissue samples to analyze the genes and molecules of these mismatched lesions. The goal was to find out if these differences mean the…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Brain radiation may erase personal memories, study warns
Knowledge-focused CompletedThis study looks at how radiation therapy for brain tumors like meningioma or pituitary adenoma might affect autobiographical memory—the memories of your life events. Researchers will ask 17 patients to complete memory tests one and two years after treatment. The goal is to see i…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New model could spare prostate cancer patients unnecessary surgery
Knowledge-focused CompletedThis study aimed to improve how doctors predict whether prostate cancer has spread to nearby lymph nodes. Researchers combined patient information, MRI scans, and genetic data from 367 men who had their prostate removed. The goal was to create a more accurate tool to help decide …
Sponsor: Francesco Montorsi • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Gene score may predict prostate cancer worsening
Knowledge-focused CompletedThis study looked at 185 men with low-risk prostate cancer who chose active surveillance (monitoring instead of immediate treatment). Researchers used a genetic test called a polygenic risk score to see if it could predict which men would have their cancer get worse over time. Th…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New study aims to predict which fibroids respond best to Non-Invasive ultrasound treatment
Knowledge-focused CompletedThis study looked at 40 women with symptomatic uterine fibroids to understand why MR-guided focused ultrasound (HIFU) works better for some than others. Researchers used MRI and contrast-enhanced ultrasound to measure fibroid blood flow, stiffness, and other features before treat…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Real-World check: ovarian cancer drug niraparib under the microscope
Knowledge-focused CompletedThis study looked back at 388 women with advanced ovarian, fallopian tube, or peritoneal cancer who were taking the drug niraparib as maintenance therapy. Researchers wanted to see how often serious side effects happened and how patients used the drug in real-life UK clinics. No …
Sponsor: Royal Marsden NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Tiny gold seeds could sharpen radiation for spine tumors
Knowledge-focused CompletedThis study tested whether implanting tiny gold markers near spinal tumors helps deliver radiation more accurately. Researchers also checked if giving slightly more radiation to the nearby esophagus is safe, which might improve tumor control. The study involved 41 adults with vari…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New surgical clip tool tested in 161 patients
Knowledge-focused CompletedThis study looked at a new device called AE05ML that helps surgeons place clips on blood vessels and other tissues during keyhole surgery. The goal was to see if the device is safe and works well. A total of 161 adults took part in the study.
Sponsor: Teleflex • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Embarrassment may be costing lives: study probes why women delay cancer checks
Knowledge-focused CompletedThis study interviewed 12 women diagnosed with gynaecological cancers (ovarian, womb, cervical, vulval, or vaginal) to understand what made them seek help or delay. Researchers focused on embarrassment and other barriers to early doctor visits. The goal is to use these insights t…
Sponsor: NHS Grampian • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Ovarian tumor study probes hidden emotional toll
Knowledge-focused CompletedThis study looked at 60 women who had surgery for borderline or benign ovarian tumors. Researchers used questionnaires to measure anxiety, depression, body image, and sexual health. The goal was to understand the emotional and psychosexual impact of a borderline tumor diagnosis c…
Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Can an app help your doctor know your family health risks?
Knowledge-focused CompletedThis study tested whether a family history app can help doctors collect and use information about patients' family health risks. Over 600 adults aged 30-69 took part. The goal was to see if the app leads to better screening and genetic referrals for conditions like cancer, heart …
Phase: NA • Sponsor: University of Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Do surgery quality rules save lives in ovarian cancer?
Knowledge-focused CompletedThis study reviewed over 11,000 patients with advanced ovarian cancer to see if hospitals that follow ten specific quality standards for surgery have better outcomes. The research looked at how long patients lived without their cancer getting worse and overall survival. The goal …
Sponsor: European Society of Gynaecological Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
AI vs. jargon: can robots make cancer info easier to read?
Knowledge-focused CompletedThis study tested whether an AI tool can help health providers write medical summaries that are easier for patients to understand. 120 providers were split into two groups: one used the AI tool, the other did not. The goal was to see if AI could improve readability and save time,…
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Joint pain from cancer drug measured in new study
Knowledge-focused CompletedThis completed study looked at how often joint pain occurs in 71 people with ovarian, colorectal, or lung cancer who were taking the drug bevacizumab. Participants filled out a questionnaire about their joint pain over 6 months. The goal was to better understand this side effect.
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Keyhole surgery blood loss study compares tying techniques
Knowledge-focused CompletedThis study looked at 60 women aged 35 to 60 who had a hysterectomy (removal of the uterus) through small cuts in the belly (laparoscopy). The goal was to compare two different methods of tying off the uterine arteries to see which one led to less blood loss during surgery. The re…
Phase: NA • Sponsor: Mostafa Bahaa • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New grid could make cancer scans sharper, safer
Knowledge-focused CompletedThis pilot study tested whether a special 2D antiscatter grid can improve the quality of cone-beam CT (CBCT) images used during radiation therapy for prostate, head and neck, and upper abdomen cancers. 43 participants received one extra CBCT scan with the grid, and researchers co…
Phase: NA • Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Fiber-Fed mice show promise against prostate cancer
Knowledge-focused CompletedThis completed study from the University of Aberdeen looked at how dietary fiber supplements might influence prostate cancer. Researchers gave mice different fibers (inulin, pectin, hemp hull) along with stool samples from healthy men over 60. They then measured changes in gut ba…
Sponsor: University of Aberdeen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Can a custom exercise plan help cancer patients on chemo? small study says maybe
Knowledge-focused CompletedThis study tested whether a flexible, personalized exercise program is practical for cancer patients receiving chemotherapy. Twenty-one adults with breast, ovarian, or colorectal cancer took part. The main goal was to see if patients would join, attend, and stick with the exercis…
Phase: NA • Sponsor: University of Dublin, Trinity College • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
10-Year study checks if HPV test alone can replace pap smear
Knowledge-focused CompletedThis study follows over 1,700 women who previously took part in a cervical cancer screening trial. Researchers want to see if testing for HPV alone is as safe and effective as combining it with a Pap smear over 10 years. Participants provide a cervical sample for both tests, and …
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Home workouts may boost cancer Patients' cell power
Knowledge-focused CompletedThis study looked at how prostate and colorectal cancer affect mitochondria—the energy factories in cells—and whether a 4-week home exercise program could improve them. Fifteen men awaiting surgery did either resistance or high-intensity interval training at home. Researchers mea…
Phase: NA • Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New drug tracking study offers no cure, but key insights for future cancer treatments
Knowledge-focused CompletedThis study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Tiny trial aims to shed light on PSMA scans in hard-to-treat prostate cancer
Knowledge-focused CompletedThis study tested whether taking dasatinib alone or with darolutamide for 14 days can increase PSMA levels on PET scans in men with metastatic prostate cancer. Only 4 men participated, all with low PSMA uptake on their initial scan. The goal was to learn more about how PSMA expre…
Phase: PHASE2 • Sponsor: St Vincent's Hospital, Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can a website help men make smarter prostate cancer screening choices?
Knowledge-focused CompletedThis study tested an online decision aid called 'Talk to Nathan About Prostate Cancer Screening' in 88 men aged 55-69. The goal was to see if it improved knowledge and helped men make clearer decisions about screening compared to standard materials. Participants used the tool or …
Phase: NA • Sponsor: David Siegel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
New EHR tool aims to boost Heart-Health talks for cancer survivors
Knowledge-focused CompletedThis study tested a tool built into electronic health records that prompts doctors to discuss heart health with cancer survivors during routine visits. Researchers enrolled 645 survivors of breast, prostate, colorectal, endometrial, and lymphoma cancers across 12 clinics. The goa…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Nepal study tests whether fighting stigma gets more women screened for cervical cancer
Knowledge-focused CompletedThis study tested a program designed to reduce stigma around cervical cancer and increase screening among women in Nepal. Researchers enrolled 310 married women aged 30-60 from one municipality. The program included educational videos and group discussions. The goal was to see if…
Phase: NA • Sponsor: Kathmandu University School of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Ovarian cancer surgery: does following guidelines save money and improve life quality?
Knowledge-focused CompletedThis study looked at whether following national guidelines for ovarian cancer surgery is cost-effective. Researchers measured the cost per quality-adjusted life year (QALY) over three years in 200 women with advanced ovarian cancer. The goal was to understand the economic impact …
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Scientists examine immune clues in ovarian cancer
Knowledge-focused CompletedThis completed study looked at tumor samples from 687 women with advanced high-grade serous ovarian cancer who were treated with chemotherapy. Researchers examined different types of immune cells in the tumors to see if they were linked to how well patients did. The goal was to b…
Sponsor: Hellenic Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Routine BRCA testing for ovarian cancer patients proves feasible in irish study
Knowledge-focused CompletedThis study tested whether it is practical to routinely check ovarian cancer tumors for BRCA gene mutations in the clinic. Researchers enrolled 200 patients with high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. They used blood and tumor samp…
Sponsor: Cancer Trials Ireland • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New biomarker may predict which cancer drugs work best
Knowledge-focused CompletedThis completed study tested whether a new biomarker called 'mass response' can predict how well a cancer therapy will work. Researchers collected tumor cells from 72 patients with various cancers through fluid drainage or biopsies. The goal was to see if this biomarker could guid…
Sponsor: Travera Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Scientists hunt for biomarkers to predict radiation damage
Knowledge-focused CompletedThis study analyzed blood, urine, and tissue samples from 273 adults with brain or lung cancer who were receiving radiation therapy. The goal was to find biological markers that could predict which patients are more likely to develop serious side effects from radiation, such as l…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Ovarian cancer drug safety check: what side effects did 354 patients report?
Knowledge-focused CompletedThis study looked at side effects of the drug niraparib (Zedula) in 354 people with ovarian cancer. Participants took niraparib capsules once a day as part of their normal care, and doctors recorded any side effects for one year. The main focus was on serious side effects like lo…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Phase: NA • Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Could T-DXd outperform standard care for multiple HER2-Positive cancers? new study investigates
Knowledge-focused CompletedThis study looks at whether the drug T-DXd works better than standard treatments for people with several types of HER2-positive solid tumors. Researchers will compare data from previous T-DXd trials with real-world medical records of patients who received standard care. The goal …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Fertility after fibroid embolization: new data from 46 women
Knowledge-focused CompletedThis study looked back at 46 women who had a procedure called uterine artery embolization to treat fibroids. The goal was to see how often women later had a baby and what pregnancy complications occurred. The researchers reviewed medical records from one hospital in France to gat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Rural cancer survivors test DIY care plans and phone education
Knowledge-focused CompletedThis study looked at whether cancer survivors living in rural areas can create their own survivorship care plans and learn from telehealth education. 261 survivors of breast, colorectal, lung, lymphoma, or prostate cancer took part. The goal was to see if this approach improves t…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Gene hunt: uncovering a hidden prostate cancer risk in martinique
Knowledge-focused CompletedThis study looked at how often a specific gene change (called HOXB13 c.853delT) occurs in men with prostate cancer in Martinique. Researchers tested 465 men of African descent who had prostate cancer. The goal was to find out how common this gene change is, which may help underst…
Phase: NA • Sponsor: University Hospital Center of Martinique • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
New study tracks hidden heart and bone risks in Cushing's disease
Knowledge-focused CompletedThis study followed 80 people with newly diagnosed Cushing's disease for three years to see how the disease affects the heart, bones, metabolism, and quality of life. Researchers used blood tests, heart scans, bone density tests, and questionnaires to track complications before a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Full or empty bladder? study tests best way to protect organs during cervical cancer radiation
Knowledge-focused CompletedThis study looked at 22 women with cervical cancer to see if having an empty bladder (using a catheter) or a full bladder (filled with 120cc of fluid) is better during a type of internal radiation called brachytherapy. The goal was to find which method lowers the radiation dose t…
Phase: NA • Sponsor: Institut de Cancérologie de Lorraine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pill-Taking habits under the microscope in advanced cancer patients
Knowledge-focused CompletedThis study looked at how closely 200 adults with advanced breast or prostate cancer follow their prescribed oral cancer treatments. Participants filled out questionnaires about their medication use and gave blood samples to check certain health markers. The goal was to understand…
Phase: NA • Sponsor: Institut de Cancérologie de Lorraine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Could a simple surgery replace lifelong hormone shots for prostate cancer?
Knowledge-focused CompletedThis study looked at whether an educational session about orchiectomy (surgery to remove the testicles) would make more men with prostate cancer choose it over lifelong hormone therapy. 101 men who were already on hormone therapy for at least a year took part. The goal was to see…
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Will patients trust AI to spot prostate cancer? new study investigates
Knowledge-focused CompletedThis completed study surveyed 51 men with localized prostate cancer and their healthcare providers in Belgium, Italy, and Spain. The goal was to understand how acceptable artificial intelligence (AI) is as a tool to help diagnose prostate cancer, and whether people are willing to…
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Liege • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Which cancer follow-up care model works best? large study seeks answers.
Knowledge-focused CompletedThis study looked at nearly 1,000 cancer survivors to find out which follow-up care model works best for their quality of life and satisfaction. Participants were breast, prostate, or colorectal cancer survivors who had finished active treatment. Researchers compared different ca…
Sponsor: George Washington University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Can a neighborhood talk save lives? prostate cancer education trial shows promise
Knowledge-focused CompletedThis study tested whether a neighborhood-based educational program could increase knowledge about prostate cancer and screening among 239 men living in high-risk areas. Participants learned about the pros and cons of screening, and researchers measured changes in decision-making …
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Eye scan may forecast vision after brain surgery
Knowledge-focused CompletedThis study tested whether a type of eye scan called OCT-angiography can predict how well vision will recover after surgery to remove a pituitary tumor. Researchers compared the scan results with standard vision tests in 21 patients. The goal was to see if the scan could serve as …
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Which ventilation method works best during robotic prostate surgery?
Knowledge-focused CompletedThis study looked at 50 men having robot-assisted prostate surgery to compare two ways of using a breathing machine: flow-controlled and volume-controlled ventilation. The goal was to see which method keeps oxygen levels better and helps the lungs work more smoothly. Researchers …
Phase: NA • Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New model predicts prostate cancer treatment response using PET scans
Knowledge-focused CompletedThis study looked at 168 men with metastatic hormone-sensitive prostate cancer to see if a model using PSMA-PET scans and routine medical information could predict how well they would respond to standard first-line treatment. The goal was to help doctors better understand which p…
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New look at Lutetium-177 for tough prostate cancers
Knowledge-focused CompletedThis study looked at over 1,200 men with advanced prostate cancer who received a radioactive drug called Lutetium-177 vipivotide tetraxetan in real-world clinics. Researchers tracked patient characteristics, treatment patterns, and PSA level reductions. The goal was to see how th…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Real-World rucaparib data: a closer look at ovarian cancer treatment
Knowledge-focused CompletedThis study reviewed medical records of 51 women with ovarian, fallopian tube, or peritoneal cancer who received the drug rucaparib in real-world clinics, not just in strict trials. Researchers looked at patient history, side effects, dosing, and how long the drug kept cancer from…
Sponsor: Grupo Español de Investigación en Cáncer de Ovario • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
PET scans may improve chemo decisions for abdominal cancer patients
Knowledge-focused CompletedThis pilot study looked at whether repeated FDG-PET/CT scans can help select patients and evaluate how well a special chemotherapy (PIPAC) works for cancer that has spread to the lining of the abdomen. 34 patients with various abdominal cancers were included. The goal was to see …
Sponsor: Odense University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Robot vs. standard surgery: which is safer for Women's cancers?
Knowledge-focused CompletedThis study looked at 386 women with cervical, uterine, or ovarian cancer to compare standard laparoscopic surgery versus robot-assisted laparoscopic surgery. The goal was to see which approach causes fewer complications within six months after the operation. Researchers tracked s…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New PET-scan method may sharpen brachytherapy for cervical cancer
Knowledge-focused CompletedThis study explores whether using a PET-scan at the start of brachytherapy (internal radiation) is feasible for patients with locally advanced cervical cancer. Fourteen participants who have already received chemoradiation will undergo an extra PET-scan during brachytherapy and a…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Michigan study tests ways to boost genetic testing in cancer patients
Knowledge-focused CompletedThis study looked at whether a special website or coaching phone calls could help more people with a personal or family history of certain cancers get genetic testing. Over 800 participants were randomly assigned to one of these two methods or to standard care. The goal was to se…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Forest in a bottle: scented oils may boost immunity after cancer treatment
Knowledge-focused CompletedThis study tested whether breathing in humidified wood or fragrant oils could mimic the immune-boosting effects of a forest walk. 28 adults who finished chemotherapy or radiation for early-stage breast or prostate cancer took part. The goal was to see if this approach is practica…
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Real-World data reveals early use of prostate cancer drug in thousands of patients
Knowledge-focused CompletedThis study examined medical records of over 6,400 prostate cancer patients who received a treatment called 177Lu-PSMA-617. Researchers wanted to understand the patients' characteristics, treatment patterns, and survival outcomes. The study did not test a new treatment but instead…
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Can adding radiation to immunotherapy help advanced cancer patients? new study explores safety and 'Abscopal' effects
Knowledge-focused CompletedThis study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Cancer drug olaparib may cause folate deficiency, small study finds
Knowledge-focused CompletedThis study checked if the cancer drug olaparib causes low folate (folic acid) levels in the blood. Ten women with advanced ovarian or breast cancer participated. Researchers measured folate levels and looked for related drops in hemoglobin. The goal was to understand side effects…
Phase: PHASE4 • Sponsor: Rush University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Tiny study tests waiting game for prostate cancer return
Knowledge-focused CompletedThis study looked at men whose prostate cancer came back after surgery, shown by a small rise in PSA. It compared giving radiation right away versus waiting and doing another special scan when PSA rose higher. Only 4 men took part, so the main goal was to see if such a study is e…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New turkish survey aims to better measure prostate cancer Patients' Well-Being
Knowledge-focused CompletedThis study translated and tested a Turkish version of the UCLA Prostate Cancer Index, a survey that measures how prostate cancer and its treatment affect daily life. Researchers worked with 115 Turkish-speaking men diagnosed with prostate cancer to check if the new version is rel…
Sponsor: Lokman Hekim University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Oxygen levels in prostate tumors may predict treatment success
Knowledge-focused CompletedThis study looked at oxygen levels inside prostate tumors in 186 men with early-stage prostate cancer. Researchers wanted to see if low oxygen (hypoxia) makes standard treatments like radiation less effective and increases the risk of cancer spreading. Participants had a special …
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New imaging tracer could reveal hidden tumor hypoxia in prostate cancer
Knowledge-focused CompletedThis study tested a special PET scan tracer called 18F-FAZA to find low oxygen areas (hypoxia) in prostate tumors. Hypoxia can make cancer harder to treat with radiation or chemo. The study involved 18 men with intermediate to high-risk or metastatic prostate cancer. The goal was…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New web tool aims to keep men with Low-Risk prostate cancer on track without unnecessary treatment
Knowledge-focused CompletedThis pilot study tested a web-based tool called MAP (Management of Active surveillance in Prostate Cancer) in 39 men aged 55+ with low-risk prostate cancer who were already on active surveillance. The tool provides education, helps coordinate care with primary care doctors, and o…
Phase: NA • Sponsor: University of Michigan Rogel Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New clinic aims to ease the journey for women cancer survivors
Knowledge-focused CompletedThis study tested whether a special survivorship clinic, combined with an app for reporting symptoms, is practical for women who have finished curative treatment for early-stage breast, cervical, or endometrial cancer. Two hundred women visited the clinic at the start and end of …
Phase: NA • Sponsor: University College Cork • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Chatbot coaches cancer survivors on genetic testing
Knowledge-focused CompletedThis study tested a digital chatbot (called CATALYST) to help cancer survivors learn about genetic testing for inherited cancer risk. Fifty adults who had certain cancers (like breast, ovarian, or prostate) used the chatbot or received usual care. The goal was to see if the chatb…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC